IL17A and atopic eczema: Th2/Th17/Th22 cytokine elevation has been observed in a subset of patients with atopic dermatitis, and the IL-23-IL-17 axis and IL-22 have been targeted by monoclonal antibodies for the treatment of atopic dermatitis (44, 45).